ShenZhen New Industries Biomedical Engineering News

Shenzhen New Industries Biomedical Engineering's (SZSE:300832) Five-year Earnings Growth Trails the 9.1% YoY Shareholder Returns

Simply Wall StMay 13 19:40 ET

ShenZhen New Industries (300832.SZ) has obtained the medical instruments registration certificate.

ShenZhen New Industries Biomedical Engineering (300832.SZ) announced that the company has received one "Medical" device certificate issued by the Guangdong Provincial Pharmaceutical Administration.

Zhitong FinanceMay 9 06:59 ET

Shenzhen New Industries Biomedical Engineering Co., Ltd. Just Missed EPS By 7.2%: Here's What Analysts Think Will Happen Next

Simply Wall StApr 28 18:59 ET

Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 79.59 Yuan From 90.31 Yuan, Keeps at Buy

MT NewswiresApr 28 07:00 ET · Ratings

New Industries: 2024 Annual Report Summary

SZSIApr 25 12:00 ET · Announcements

New Industries: 2024 Annual Report

SZSIApr 25 12:00 ET · Announcements

New Industries: Report for the first quarter of 2025

SZSIApr 25 12:00 ET · Announcements

Analysts Have Lowered Expectations For Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832) After Its Latest Results

Simply Wall StApr 12 20:46 ET

ShenZhen New Industries Biomedical Engineering (300832.SZ): This adjustment in the USA tariff policy has a relatively limited direct impact on the company's overseas Business.

On April 8, Gelonghui reported that ShenZhen New Industries Biomedical Engineering (300832.SZ) stated on the investor interaction platform that the company has determined the direct impact of the recent USA tariff policy adjustment on its overseas Business is relatively limited. By region, the company's Business growth performance in Europe and Latin America for 2024 is outstanding, while revenue from the USA accounts for less than 0.1% of overseas revenue. The company will insist on technology innovation as its core competitive advantage. Regardless of how the external environment changes, the company will continue to launch more competitive products to meet the needs of clinical end-users and increase market share. The company will continue to adhere to deepening efforts in overseas markets.

Gelonghui FinanceApr 8 05:41 ET

ShenZhen New Industries Biomedical Engineering (300832.SZ) performance report: For the fiscal year 2024, the net income attributable to the parent company is 1.828 billion yuan, representing a year-on-year growth of 10.57%.

On April 8, Gelonghui reported that ShenZhen New Industries Biomedical Engineering (300832.SZ) announced its performance quick report for the year 2024. In 2024, the company achieved revenue of 4.535 billion yuan, a year-on-year increase of 15.41%; total profit of 2.093 billion yuan, a year-on-year increase of 10.57%; net income attributable to shareholders of the listed company of 1.828 billion yuan, a year-on-year increase of 10.57%; net income attributable to shareholders of the listed company after excluding non-recurring gains and losses of 1.72 billion yuan, a year-on-year increase of 11.19%; and basic EPS of 2.3271 yuan/share.

Gelonghui FinanceApr 8 04:53 ET

Express News | New Industries Biomedical Prelim 2024 Net Profit up 10.6% Y/Y

ReutersApr 8 04:35 ET

New Industries: 2024 Annual Results Report Announcement

SZSIApr 8 04:30 ET · Announcements

ShenZhen New Industries Biomedical Engineering (300832.SZ) has received IVDR CE certification for multiple products.

ShenZhen New Industries Biomedical Engineering (300832.SZ) announced that 73 of its products have been certified by the EU notification body - TÜV SÜD...

Zhitong FinanceMar 26 06:04 ET

Shenzhen New Industries Biomedical Engineering (SZSE:300832) Is Reinvesting To Multiply In Value

Simply Wall StMar 26 01:05 ET

Vivo announced the establishment of a Siasun Robot&Automation Lab, focusing on incubating the "brain" and "eyes" of robots, primarily targeting the Consumer market.

Sina Technology News, on the afternoon of March 25, during the Boao Forum for Asia Annual Conference 2025, as a member of the Boao Forum Advisory Council and a strategic partner for four consecutive years, vivo showcased its latest technological achievements, including its blue technology matrix, vivo mixed reality headset, and advancements in the 6G field at the Boao venue. During the "Release Moment" segment held on the afternoon of the 25th, Hu Baishan, Executive Vice President, Chief Operating Officer of vivo, and Director of the vivo Central Research Institute delivered a keynote speech titled "Technology as a Tool, Humanism as a Path." In the speech, Hu Baishan mentioned that the mobile phone industry is a reflection of China's Technology innovation, and vivo is at the forefront.

Sina TechnologyMar 25 04:41 ET

On March 11, A-share investment warning needle | Guanggang Gas: Shareholder Jinggangshan Chuanxing plans to reduce its Shareholding by no more than 2%; HengFeng Information Technology: No revenue has been formed within the scope of the "DeepSeek", "AI Asi

Shareholders of ShenZhen New Industries Biomedical Engineering, Sequoia Capital, plan to reduce their stake by no more than 1%; shareholders of Guanggang Gas, Jinggangshan Chengxing, plan to reduce their stake by no more than 2%; Beijing Jingcheng Machinery Electric stated that the sales revenue from hydrogen-related products is expected to account for about 4.22% of the company's main Business revenue from January to September 2024; Hl Corp (Shenzhen) does not have any major matters such as mergers, acquisitions, or reorganizations related to general Siasun Robot&Automation in the planning stage; Jiangsu Jingyuan Environmental Protection Co.,Ltd. stated that Cloud Computing-related Business comprises a relatively small proportion of the company's overall Business structure; HengFeng Information Technology has not generated operating income within the scope of the "DeepSeek", "AI Agents", and "Robot" Concept.

Gelonghui FinanceMar 10 10:13 ET

Gelonghui Announcement Selection | Jinhui Co., Ltd.: The net income for 2024 is 0.477 billion yuan, a year-on-year increase of 39.06%, and a proposed cash dividend of 2.20 yuan; HengFeng Information Technology: Has not generated revenue within the scope o

【Hot News】Beijing Jingcheng Machinery Electric (600860.SH): Sales revenue from hydrogen-related products accounts for approximately 4.22% of the company's main Business income from January to September 2024. Hl Corp (Shenzhen) (002105.SZ): There are no significant matters such as mergers and acquisitions or reorganizations involving general Siasun Robot&Automation that are in the planning stage. Jiangsu Jingyuan Environmental Protection Co.,Ltd. (688096.SH): Cloud Computing related business accounts for a relatively small proportion of the company's overall business structure. Xince Standards (300938.SZ): The joint venture 'Shenzhen Xince Standards Robot Technology Co., Ltd.' is still in the establishment process. HengFeng Information Technology (300605.SZ): Not finalized.

Gelonghui FinanceMar 10 10:10 ET

Express News | New Industries Biomedical Says Major Shareholder Plans to Unload up to 1% Stake in the Company Within Three Months

ReutersMar 10 08:23 ET

Does Shenzhen New Industries Biomedical Engineering (SZSE:300832) Deserve A Spot On Your Watchlist?

Simply Wall StMar 6 17:45 ET

ShenZhen New Industries Biomedical Engineering (300832.SZ): Hepatitis B Virus Surface Antigen Detection Kit (Magnetic Microparticle Chemiluminescence Method) has received IVDR CE certification.

ShenZhen New Industries Biomedical Engineering (300832.SZ) announced that the company's product, the Hepatitis B Virus Surface Antigen Detection Kit (magnetic micro-particle...)

Zhitong FinanceMar 4 05:43 ET